Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amylyx PharmaceuticalsAMLX -1.07%33 Earnings per Share (Diluted) is $-1.43 as of Jun. 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 788 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks better than 70.18% on this metric.
During the past 3 years, the average EPS without NRIGrowth Rate was 23.30% per year.
During the past 7 years, Amylyx Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 23.30% per year. The lowest was -119.20% per year. And the median was -30.80% per year.
Amylyx Pharmaceuticals (NAS:AMLX) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Amylyx Pharmaceuticals Earnings per Share (Diluted) Related Terms
Amylyx Pharmaceuticals Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Amylyx Pharmaceuticals's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals Earnings per Share (Diluted) Chart
AMLX vs ANIP, PBH, BCRX: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's PE Ratio falls into.
Amylyx Pharmaceuticals Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Amylyx Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-1.43 mean?
Amylyx Pharmaceuticals (AMLX) has a Earnings per Share (Diluted) of $-1.43 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Amylyx Pharmaceuticals and its competitors. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #235 out of 788 companies in the Drug Manufacturers industry, placing it in the top 29.8%.
Is Amylyx Pharmaceuticals' Earnings per Share (Diluted) too high?
Amylyx Pharmaceuticals' current Earnings per Share (Diluted) is $-1.43. Based on the distribution chart, Amylyx Pharmaceuticals ranks #235 out of 788 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' Earnings per Share (Diluted) compare to ANIP and PBH?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #235 out of 788 companies for Earnings per Share (Diluted). This puts Amylyx Pharmaceuticals in the upper half of its industry. The industry median Earnings per Share (Diluted) is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.60, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Amylyx Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current Earnings per Share (Diluted) is $-1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current Earnings per Share (Diluted) of $-1.43. The current Earnings per Share (Diluted) is $-1.43. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current Earnings per Share (Diluted) is $-1.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score
Get the complete analysis for AMLX
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 
